(Press-News.org)
As Streptococcus A cases continue to be prevalent in Queensland and internationally, a new nasal vaccine could provide long-term protection from the deadly bacteria.
Associate Professor Manisha Pandey, Professor Michael Good, and their team from Griffith University’s Institute for Glycomics, are leading the development of a Strep A vaccine which is currently in Phase 1 clinical trials in Canada and quickly advancing to Phase 2 efficacy trials.
The team’s new preclinical research, recently published in Nature Communications, shows an experimental liposome-based vaccine approach incorporating a conserved M-protein epitope from Strep A and an immunostimulatory glycolipid (3D(6-acyl) PHAD) administered via the nasal passage, can provide long-term mucosal protection against Strep A.
Lead author Dr Victoria Ozberk said studies have shown most pathogens enter or colonise via the soft tissue in the upper respiratory tract, which is essentially the highway to the rest of the body.
“This has the potential to be a world-first as there are currently no subunit vaccines that target the upper respiratory tract due to a lack of licenced immunostimulants suitable for human use,” Dr Ozberk said.
“We demonstrated that a liposomal mucosal vaccination strategy can induce robust local protective immunity.”
Associate Professor Pandey said the team found PHAD plays an augmenting role in inducing enduring humoral and cellular immunity, which was evident for at least one-year post-vaccination.
“The longevity of immune response is a critical hallmark of successful vaccination and therefore the findings from this study are highly significant,” she said.
Professor Good said: “In the future, this vaccine platform could pave the way for other mucosal pathogens.”
Group A Streptococcus is a global human pathogen that leads to a wide range of infections from illnesses such as mild pharyngitis and impetigo to invasive diseases such as toxic shock syndrome, necrotising fasciitis, and cellulitis.
Professor Mark von Itzstein AO, Director of the Institute for Glycomics, welcomed these research findings.
“This platform provides a real shot at developing a new direction for vaccine discovery against significant infectious pathogens that cause serious and life-threatening diseases,” he said.
Immunity to Strep A takes several years to develop, and currently, there is no vaccine available.
Moreover, repeated infections can lead to the post-streptococcal sequelae of rheumatic fever and rheumatic heart disease, for which the Australian Indigenous population bears the highest disease burden globally.
Strep A causes 700 million human infections each year and there are more than 500,000 deaths globally.
The team has developed a Strep A vaccine which is currently being tested in a human clinical trial in Canada.
The paper ‘A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils’ has been published in Nature Communications.
END
SAN ANTONIO, Oct. 5, 2023 – Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio (UT Health San Antonio) have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment.
The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of Health that will pave the way for a clinical trial next year for patients with advanced lung cancer. The research is detailed in a new article in Cell Reports, ...
London mayor Sadiq Khan’s efforts to expand the capital’s Ultra Low Emission Zone (ULEZ) as part of a push to reduce air pollution and improve health, is politically courageous and an example for mayors around the world, says the World Health Organization’s environment, climate change and health director, Maria Neira.
In an exclusive interview for The BMJ’s climate issue, Neira says she is tired of listening to politicians speak on climate change as if they didn't have the power to ...
Researchers have conducted trials using a software capable of detecting intricate details of emotions that remain hidden to the human eye.
The software, which uses an ‘artificial net’ to map key features of the face, can evaluate the intensities of multiple different facial expressions simultaneously.
The University of Bristol and Manchester Metropolitan University team worked with Bristol’s Children of the 90s study participants to see how well computational methods could capture authentic human emotions amidst everyday ...
The Keck School of Medicine of USC has received $2 million from the California Institute of Regenerative Medicine (CIRM) to further augment its newly launched cGMP Laboratory, a state-of-the-art facility designed to advance early-stage research into clinically viable cell and gene therapies. To expedite the translation of these therapies from the lab to the clinic, the facility needs advanced technological know-how, streamlined operations and strict protocols for developing and testing these products, all of which ...
HOUSTON (October 4, 2023) – Texas Children’s Hospital is proud to announce that its Adolescent Bariatric Surgery Program has received national accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP).
Texas Children’s Hospital The Woodlands is the only Bariatric Surgery Center in the state of Texas that serves to an adolescent-only patient population with a multidisciplinary clinical staff who is certified to meet the surgical, medical and psychological needs of ...
Some of the thinnest materials known to mankind may provide solutions to scientists in their quest to curb the effects of global warming.
Known as MXene and MBene compounds, these substances are only a few atoms thick, making them two-dimensional. Because of their large surface area, the materials have the potential to absorb carbon dioxide molecules from the atmosphere, which could help reduce the harmful effects of climate change by safely sequestering carbon dioxide.
In a paper published Oct. 4 in the journal Chem, UC Riverside professor Mihri Ozkan and her co-authors explain the potential of MXenes and MBenes in carbon capture technologies.
“In this review, ...
CORVALLIS, Ore. – Fossil researchers have discovered a novel genus and species of tiny wasp with a mysterious, bulbous structure at the end of each antenna.
The female micro-wasp was described from 100-million-year-old Burmese amber in a study led by George Poinar Jr., who holds a courtesy appointment in the Oregon State University College of Science.
Poinar and Fernando Vega, an independent researcher based in Silver Spring, Maryland, have some ideas about the “clouds” on the ...
Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.
Tirzepatide belongs to a new class of drugs that mimic the effect of two hormones involved in blood sugar control and appetite suppression, ...
New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has identified a range of characteristics associated with a higher risk of sudden cardiac arrest in individuals with type 2 diabetes.
These include the some commonly prescribed antibiotic and antipsychotic drugs, prokinetics (drugs used to treat gastrointestinal symptoms such as nausea and vomiting) and low fasting blood sugar.
Sudden cardiac arrest (SCA) is a leading cause of death. ...
New research presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Hamburg (2-6 Oct), reveals a marked increase in several common conditions in the years leading up to, and immediately prior to, type 2 diabetes diagnosis, suggesting considerably earlier diagnosis might be possible in some patients.
“These novel insights into the onset and natural progression of type 2 diabetes, suggest an early phase of inflammation-related disease activity long before any clinical diagnosis of type 2 diabetes is made”, says senior author Dr Adrian Heald from Manchester ...
